Infant Bacterial Therapeutics AB (publ) announces that the Nomination Committee is appointed for the Annual General Meeting 2018
The Annual General Meeting of 2017 decided that the Nomination Committee would be appointed as follows: "The Chairman of the Board shall convene the three largest shareholders in the Company, who...
November 8, 2017
European Medicines Agency adopts a positive opinion on the Paediatric Investigation Plan for IBT’s lead product
The Paediatric Committee (PDCO) at the European Medicines Agency (EMA) has adopted a positive opinion on the Paediatric Investigation Plan (PIP) proposed by IBT for the development of IBP-9414 for...
September 28, 2017
Infant Bacterial Therapeutics announces that top line data demonstrate similar safety and tolerability profile in the active and placebo groups.
Infant Bacterial Therapeutics and the principal investigator Dr. Josef Neu have made an initial evaluation of the top line data of the Phase II “Randomized, double blind, parallel-group,...
September 11, 2017
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – June 30, 2017
Message from the CEO   IBT are currently in the completion stage of the phase II clinical trial (NCT02472769) and are concurrently working with preparations for a subsequent phase III...
August 28, 2017
Annual General Meeting of Infant Bacterial Therapeutics AB (publ)
The Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 4, 2017 voted to approve the following resolutions:   Adoption of the annual report Discharge from...
May 4, 2017
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – March 31, 2017
Message from the CEO IBTs operations will during the current year be focused on completion of the ongoing Phase ll study and planning of the following clinical Phase lll study of IBP-9414. As...
May 4, 2017
Infant Bacterial Therapeutics AB (publ) Annual Report for 2016 has now been published
Infant Bacterial Therapeutics AB (publ) Annual Report 2016 is now available on the companies website www.ibtherapeutics.com.   A physical copy of the Annual Report can also be...
April 6, 2017
Annual General Meeting of Infant Bacterial Therapeutics AB (publ)
Infant Bacterial Therapeutics AB (publ) will hold its Annual General Meeting at 2:00 p.m. on Thursday, 4 May 2017, at Citykonferensen Ingenjörshuset, Malmskillnadsgatan 46,...
April 5, 2017
Infant Bacterial Therapeutics AB (publ), (IBT) has been approved for listing on Nasdaq First North’s Premier segment.
Infant Bacterial Therapeutics AB (publ) (“IBT”), today traded on Nasdaq First North, has applied and been approved for listing on Nasdaq First North’s Premier segment. Companies which are...
March 10, 2017
Infant Bacterial Therapeutics AB (publ), (IBT) Interim report January 1 – December 31 2016
Message from the CEO “During the month of June, the first patients were recruited and dosed in IBTs clinical study, IBP-9414, in the USA.  The last patient was recruited on January 23, 2017...
February 14, 2017
Last patient enrolled in IBT’s Phase 2 study
Infant Bacterial Therapeutics AB (publ) (“IBT”) announces that the last premature infant has now been enrolled and recruitment to the Phase 2 study is now closed.   The Phase 2 study...
January 24, 2017
IBT adds new indication for Gastroschisis-Related Intestinal Dysfunction
Infant Bacterial Therapeutics AB (publ) (“IBT”), a pharmaceutical company that develops drugs that meet the medical needs of premature infants, is in the early planning stages of developing a...
December 14, 2016
Positive recommendation from the independent Data Safety Monitoring Board to continue Phase II Study
IBT announces that the second and last planned evaluation of safety data by the independent Data Safety Monitoring Board (DSMB), in the ongoing Phase II clinical study, was performed on...
November 21, 2016
Infant Bacterial Therapeutics AB appoints new CFO
Infant Bacterial Therapeutics AB (publ.) (“IBT”) is pleased to announce the appointment of Daniel Mackey as Chief Financial Officer (CFO) from January 2017 replacing Michael Owens in this role....
October 12, 2016
Infant Bacterial Therapeutics AB (publ), (IBT) Interim report January 1 – June 30 2016
Message from the CEO “In June we announced that the first premature infant had been enrolled and dosed in the Company´s Phase ll clinical trial. This Phase ll trial is a randomized,...
August 19, 2016
Infant Bacterial Therapeutics enrolls First Patient in Phase 2 Clinical Trial
Infant Bacterial Therapeutics AB (publ) (“IBT”) announces that the first premature infant has been enrolled and dosed in the Company´s Phase 2 clinical trial. This Phase 2 trial is a...
June 7, 2016
IBT’s rights issue fully subscribed
The result of Infant Bacterial Therapeutics AB’s (“IBT” or the “Company”) rights issue, for which the subscription period ended on 23 May 2016, indicates that 3,575,583 shares,...
May 26, 2016
Prospectus relating to IBT’s rights issue published
To access the press release, please read the following disclaimer here.
April 27, 2016
IBT announces fully underwritten SEK 100 million rights issue
To access the press release, please read the following disclaimer here.
April 27, 2016
IBT receives Rare Pediatric Disease Designation from FDA for drug candidate
Infant Bacterial Therapeutics AB (publ) (“IBT”) announces that the U.S. Food and Drug Administration (FDA) has awarded IBT Rare Pediatric Disease Designation for its drug candidate IBP-9414,...
March 31, 2016
Infant Bacterial Therapeutics is listed on Nasdaq First North and publishes company description
Infant Bacterial Therapeutics AB (publ) (“IBT”) has been approved for listing and the company’s series B shares will be traded on Nasdaq First North as from 29 March 2016 with Erik Penser...
March 21, 2016
Proposal for distribution and separate listing of Infant Bacterial Therapeutics from BioGaia
The board of directors of parent company BioGaia AB (publ) has resolved to propose to an Extraordinary General Meeting in BioGaia on 18 March 2016 to distribute the shares in the subsidiary Infant...
February 19, 2016
IBT has U.S. IND open and Swedish CTA approved for clinical study
IBT announces today that the IND (Investigational New Drug) for the prevention of necrotizing enterocolitis (NEC), has been accepted by the FDA (U.S. Food and Drug Administration). Furthermore, IBT...
January 8, 2016
IBT receives additional funding from BioGaia
Infant Bacterial Therapeutics plans to start a study on the safety and tolerability of the product in 2015. To allow for the study start, BioGaia will support IBT with an additional investment of 520...
March 26, 2015
Orphan Drug Designation in Europe
Infant Bacterial Therapeutics has now obtained the Orphan Drug Designation for Lactobacillus reuteri for the prevention of necrotizing enterocolitis in Europe. Read the official press release here
February 23, 2015
FDA approves orphan drug designation
Necrotizing enterocolitis (NEC) is a rare and extremely severe disease that affects premature infants. The FDA Office of Orphan Product Development has approved the request. Read the official press...
February 21, 2014
BioGaia invests in a drug against NEC
The board of BioGaia has decided to invest in the first phase of a long-term project aimed at developing a drug with rigorous hygiene, analysis and documentation requirements, to treat the highly...
February 21, 2014